Page 67 - Amgen News Today

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Amgen Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...

By Ian Walker Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the companys denosumab biosimilars products, paving the way for it to launch its bone...

Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) and Amgen (NASDAQ:AMGN – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation. Insider and Institutional Ownership 83.6% of Vigil Neuroscience shares […]

Amgen (NASDAQ:AMGN – Get Free Report) and Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent recommendations […]

The S&P500 ended in the green for the fifth time in six sessions, the same for the Nasdaq Composite with +0.35%, with the Dow Jones coming out on top with +0.38%.Tesla , Boeing and Apple supported...

BioPharma

Sen. Sherrod Brown (D-OH) takes cash from Big Pharma companies and lobbyists despite saying the industry must be punished for jacking up drug prices.

The pharma industry’s COVID-peak in corporate reputation has begun to drop, though it still remains higher than pre-pandemic levels.